Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

10.5%

2 terminated/withdrawn out of 19 trials

Success Rate

88.9%

+2.4% vs industry average

Late-Stage Pipeline

21%

4 trials in Phase 3/4

Results Transparency

31%

5 of 16 completed trials have results

Key Signals

5 with results

Enrollment Performance

Analytics

Phase 1

8(42.1%)

Phase 2

7(36.8%)

Phase 3

4(21.1%)

19Total

Phase 1(8)

Phase 2(7)

Phase 3(4)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (19)

Showing 19 of 19 trials

NCT05065619Phase 1Terminated

Safety Immunogenicity Study of MT-2766 in Japanese Adults（COVID-19）

Role: lead

NCT03301051Phase 3Completed

Efficacy, Safety, and Immunogenicity of a Plant-Derived Quadrivalent Virus-Like Particles (VLPs) Influenza Vaccine in Adults

Role: lead

NCT03321968Phase 3Completed

Lot-to-lot Consistency of a Plant-Derived Quadrivalent Virus-Like Particles Influenza Vaccine in Healthy Adults

Role: lead

NCT04622592Phase 1Completed

Adjuvanted Seasonal Recombinant Quadrivalent Virus-Like Particles (QVLP) Influenza Vaccine in Adults 65 Years of Age and Older

Role: lead

NCT03739112Phase 3Completed

Efficacy of a Plant-derived Quadrivalent Virus-like Particle (VLP) Vaccine in the Elderly

Role: lead

NCT05040789Phase 3Withdrawn

Phase 3 Study to Evaluate the Lot Consistency of a Recombinant Coronavirus-Like Particle COVID-19 Vaccine

Role: lead

NCT04636697Phase 2Active Not Recruiting

Study of a Recombinant Coronavirus-Like Particle COVID-19 Vaccine in Adults

Role: lead

NCT04450004Phase 1Completed

Safety, Tolerability and Immunogenicinity of a Coronavirus-Like Particle COVID-19 Vaccine in Adults Aged 18-55 Years.

Role: lead

NCT01991561Phase 2Completed

Immunogenicity, Safety, Tolerability of a Plant-made H5 Virus-like-particle (VLP) Influenza Vaccine.

Role: lead

NCT02768805Phase 2Completed

Immunogenicity of a Quadrivalent Virus-Like Particles (VLP) Influenza Vaccine in Healthy Adults

Role: lead

NCT01991587Phase 1Completed

Safety, Tolerability and Immunogenicity of a Plant-made Seasonal Quadrivalent VLP Influenza Vaccine in Adults

Role: lead

NCT02233816Phase 2Completed

Immunogenicity, Safety and Tolerability of a Plant-Derived Seasonal Virus-Like-Particle Quadrivalent Influenza Vaccine in Adults

Role: lead

NCT02236052Phase 2Completed

Immunogenicity, Safety and Tolerability of a Plant-Derived Seasonal VLP Quadrivalent Influenza Vaccine in the Elderly Population

Role: lead

NCT02831751Phase 2Completed

Immunogenicity, Safety, and Tolerability of a Plant-Derived Quadrivalent VLP Influenza Vaccine in Elderly Adults

Role: lead

NCT02022163Phase 1Completed

Safety, Tolerability and Immunogenicity of a Plant-made H7 Virus-like Particle (VLP) Influenza Vaccine in Adults.

Role: lead

NCT01657929Phase 1Completed

H5-VLP + GLA-AF Vaccine Trial in Healthy Adult Volunteers

Role: collaborator

NCT01302990Phase 1Completed

Safety, Tolerability and Immunogenicity of a Plant-Made H1 VLP Influenza Vaccine in Adults

Role: lead

NCT01244867Phase 2Completed

Immunogenicity, Safety, Tolerability of a Plant-Made H5 VLP Influenza Vaccine

Role: lead

NCT00984945Phase 1Completed

Safety Study of a Plant-based H5 Virus-Like Particles (VLP) Vaccine in Healthy Adults

Role: lead

All 19 trials loaded